CCN3 Proteins as a diagnostic marker in osteosarcoma patients: A case control study. (2021)

• Record Type: Journal Article
• Authors: Siddiqui, Salma; Pandey, Vaishnavi; Ali, Sabir; Singh, Ajai; Sharma, Dilutpal; Yadav, Manish; Raikwar, Archana
• Is Part Of: Cancer treatment and research communications. Number 28(2021)
• Publication Date: 2021
• Subjects: Osteosarcoma -- Diagnostic marker -- Biomarker -- CCN3, Proteomic analysis
• DOI: 10.1016/j.ctarc.2021.100381
• Languages: English
• ISSNs: 2468-2942

Abstract

Highlights: Osteosarcoma is the most prevalent type of primary bone sarcoma and is the major cause of deaths associated with cancer in children and adolescents. Despite novel and innovative therapies, early diagnosis of the osteosarcoma still critically needed. The CCN3 protein is mechanistically involved in the development of osteosarcoma, indicating that they represent a promising new class of bone cancer biomarkers. The CCN3 protein expressions were significantly up-regulated in tissue samples of osteosarcoma (cases) compared to controls. The up-regulated CCN3 protein expressions in osteosarcoma tissue along with significant differential manifestation as per different grades of osteosarcoma make CCN3 suitable for a potential diagnostic/prognostic biomarker. Abstract: Background: Osteosarcoma is the most prevalent type of primary bone sarcoma and is the major cause of deaths associated with cancer in children and adolescents. Despite novel and innovative therapies, early diagnosis of the osteosarcoma is still critically needed. Our study aimed to analyse the CCN3 proteins as a diagnostic marker and correlate their expression level with the severity of primary osteosarcoma patients. Methods: In this prospective case-control study, after ethical clearance and informed consent, a total of 35 cases with primary osteosarcoma and ten otherwise healthy controls were enroled according to our strict inclusion-exclusion criteria. Tissue samples were collected during biopsy procedures in suspected cases and in controls during bone grafting procedures. The CCN3 expression level was measured by the western blotting assay. The clinic-radiological examinations were done in cases and graded according to the AJCC classification. Comparisons of CCN3 expression were measured between cases and controls, followed by correlation of their expression level with severity/grade of osteosarcoma in cases. Results: All the demographic parameters showed insignificant differences. The CCN3 protein expressions were significantly upregulated in tissue samples of osteosarcoma patients (cases) compared to controls. The mean difference ( p <0.0001) in CCN3 protein expression between cases' and controls' bony tissues was significant but showed insignificant correlation with the different grades of osteosarcoma. Conclusions: The upregulated CCN3 protein expression in osteosarcoma tissue along with significant differential manifestation in accordance with different grades of osteosarcoma make CCN3 suitable for a potential diagnostic biomarker. However, the author recommends further extensive multi-centric collaborative studies to increase our study reliability and generalizability.